AA
VIRX

AlphaMark Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

AlphaMark Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200
Closed -$1K – 748
2022
Q3 		$1K Hold
200
– – ﹤0.01% 673
2022
Q2 		$1K Buy
+200
New +$570 ﹤0.01% 616

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

AlphaMark Advisors's VIRX Position: Q4 2022 in Review

AlphaMark Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2022, closing a stake of 200 shares — an estimated $1K sold.

AlphaMark Advisors first reported a position in VIRX in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 56 funds tracked by Wall St. Rank hold VIRX as of Q4 2022.

  • AlphaMark Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • AlphaMark Advisors sold 200 Viracta Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1K.
  • AlphaMark Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • AlphaMark Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2022.
  • 56 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2022.

Based on AlphaMark Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.